Nanjing CoreTech biomedical Co.,Ltd. welcome visit website http://www.china-core-tech.com. which is controlled by the Nanjing New Industrial Investment Group was founded in 2002.The company which takes the aim at industrialization is a biomedical research institute. It has two core businesses which are API and intermediate research and industrialization, biomedical R and D outsourcing.
In the aspect of API and pharmaceutical intermediates, such as CAS 475086-01-2,656247-18-6,856867-55-5,69559-11-1,913611-97-9,41294-56-8,54573-75-0,93129-94-3,111594-58-2.the company has successfully developed more than 120 new drugs，of which 70 can be long-term stably supplied to domestic and foreign customers. The quality of Products achieve to international standards such as European pharmacopoeia standard, American pharmacopoeia standard. In the aspect of biomedical R and D outsourcing, the company has developed 4 innovative medicines and got 26 drug registration approvals of CFDA.
The company with 41 patents at home and abroad won 50 science projects from government. It is the "International cooperation Demonstration base", " Biomedical science and Technology public service platform of Jiangsu Province"," Enterprise Academician workstation of Jiangsu Province " etc.
The R & D and incubation center of the company is 26,000 square meters. It has built a drug development, life sciences technology and CMO platform. The professional R and D team contains many Ph.D.S and overseas high-level talents, they are specialist in drug discovery, research, registration, clinical CRO and so on. It can provide more than 500 professional services for the biomedical and related fields.
In recent years, the company constantly enriched international technology transfer, university-industry cooperation, high-level innovative entrepreneurial talent and R & D outsourcing resourses. Carrying out industry-college-research cooperation with Chen Yuanhong academician of Nanjing University, Zhang Yaoming academician of Southeast University and establishing strategic cooperation with Cels Inc, Technology links2 Inc of England, XBL Inc of American, Xiansheng Pharmaceutical Co.,Ltd, Yangzijiang Pharmaceutical Co.,Ltd and so on.
In the aspect of API and pharmaceutical intermediates, such as CAS 475086-01-2,656247-18-6,856867-55-5,69559-11-1,913611-97-9,41294-56-8,54573-75-0,93129-94-3,111594-58-2.the company has successfully developed more than 120 new drugs，of which 70 can be long-term stably supplied to domestic and foreign customers. The quality of Products achieve to international standards such as European pharmacopoeia standard, American pharmacopoeia standard. In the aspect of biomedical R and D outsourcing, the company has developed 4 innovative medicines and got 26 drug registration approvals of CFDA.
The company with 41 patents at home and abroad won 50 science projects from government. It is the "International cooperation Demonstration base", " Biomedical science and Technology public service platform of Jiangsu Province"," Enterprise Academician workstation of Jiangsu Province " etc.
The R & D and incubation center of the company is 26,000 square meters. It has built a drug development, life sciences technology and CMO platform. The professional R and D team contains many Ph.D.S and overseas high-level talents, they are specialist in drug discovery, research, registration, clinical CRO and so on. It can provide more than 500 professional services for the biomedical and related fields.
In recent years, the company constantly enriched international technology transfer, university-industry cooperation, high-level innovative entrepreneurial talent and R & D outsourcing resourses. Carrying out industry-college-research cooperation with Chen Yuanhong academician of Nanjing University, Zhang Yaoming academician of Southeast University and establishing strategic cooperation with Cels Inc, Technology links2 Inc of England, XBL Inc of American, Xiansheng Pharmaceutical Co.,Ltd, Yangzijiang Pharmaceutical Co.,Ltd and so on.
